Alice Muglia Amancio
Alice Muglia Amancio has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Alan Sher
Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
2 shared publications - Dragana Jankovic
Immunoparasitology Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
2 shared publications Ademar Lopes
Urology Division, Department of Pelvic Surgical Oncology, A.C. Camargo Cancer Center, 01508-010, São Paulo, SP, Brazil
1 shared publication- Adriele de Freitas Neiva Lessa
Hospital do Câncer de Muriaé
1 shared publication - Ahmed Aziz Bousfiha
Laboratory of Clinical Immunology, Infection and Autoimmunity (LICIA), Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Casablanca P.O. Box 9154, Morocco
1 shared publication - Alejandro Nieto-Patlán
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France
1 shared publication
Latest Publications
- Open Access
- 22 April 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (3) , 501352
Differential melanoma outcomes in men and women: longitudinal findings from a ten-year study
- 22 April 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (3) , 501352
Open AccessDifferential melanoma outcomes in men and women: longitudinal findings from a ten-year study
- Open Access
- 8 March 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (4)
A partial form of inherited human USP18 deficiency underlies infection and inflammation
Human USP18 is an interferon (IFN)-stimulated gene product and a negative regulator of type I IFN (IFN-I) signaling. It also removes covalently linked ISG15 from proteins, in a process called deISGylation. In turn, ISG15 prevents USP18 from being degraded by the proteasome. Autosomal recessive complete USP18 deficiency is life-threatening in infancy owing to uncontrolled IFN-I–mediated autoinflammation. We report three Moroccan siblings with autoinflammation and mycobacterial disease who are homozygous for a new USP18 variant. We demonstrate that the mutant USP18 (p.I60N) is normally stabilized by ISG15 and efficient for deISGylation but interacts poorly with the receptor-anchoring STAT2 and is impaired in negative regulation of IFN-I signaling. We also show that IFN-γ–dependent induction of IL-12 and IL-23 is reduced owing to IFN-I–mediated impairment of myeloid cells to produce both cytokines. Thus, insufficient negative regulation of IFN-I signaling by USP18-I60N underlies a specific type I interferonopathy, which impairs IL-12 and IL-23 production by myeloid cells, thereby explaining predisposition to mycobacterial disease.
- 8 March 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (4)
Open AccessA partial form of inherited human USP18 deficiency underlies infection and inflammation
Human USP18 is an interferon (IFN)-stimulated gene product and a negative regulator of type I IFN (IFN-I) signaling. It also removes covalently linked ISG15 from proteins, in a process called deISGylation. In turn, ISG15 prevents USP18 from being degraded by the proteasome. Autosomal recessive complete USP18 deficiency is life-threatening in infancy owing to uncontrolled IFN-I–mediated autoinflammation. We report three Moroccan siblings with autoinflammation and mycobacterial disease who are homozygous for a new USP18 variant. We demonstrate that the mutant USP18 (p.I60N) is normally stabilized by ISG15 and efficient for deISGylation but interacts poorly with the receptor-anchoring STAT2 and is impaired in negative regulation of IFN-I signaling. We also show that IFN-γ–dependent induction of IL-12 and IL-23 is reduced owing to IFN-I–mediated impairment of myeloid cells to produce both cytokines. Thus, insufficient negative regulation of IFN-I signaling by USP18-I60N underlies a specific type I interferonopathy, which impairs IL-12 and IL-23 production by myeloid cells, thereby explaining predisposition to mycobacterial disease.
- Open Access
- 24 February 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (7) , 1642-1652
IFNs Reset the Differential Capacity of Human Monocyte Subsets to Produce IL-12 in Response to Microbial Stimulation
Human primary monocytes are composed of a minor, more mature CD16+(CD14low/neg) population and a major CD16neg(CD14+) subset. The specific functions of CD16+ versus CD16neg monocytes in steady state or inflammation remain poorly understood. In previous work, we found that IL-12 is selectively produced by the CD16+ subset in response to the protozoan pathogen, Toxoplasma gondii. In this study, we demonstrated that this differential responsiveness correlates with the presence of an IFN-induced transcriptional signature in CD16+ monocytes already at baseline. Consistent with this observation, we found that in vitro IFN-γ priming overcomes the defect in the IL-12 response of the CD16neg subset. In contrast, pretreatment with IFN-γ had only a minor effect on IL-12p40 secretion by the CD16+ population. Moreover, inhibition of the mTOR pathway also selectively increased the IL-12 response in CD16neg but not in CD16+ monocytes. We further demonstrate that in contrast to IFN-γ, IFN-α fails to promote IL-12 production by the CD16neg subset and blocks the effect of IFN-γ priming. Based on these observations, we propose that the acquisition of IL-12 responsiveness by peripheral blood monocyte subsets depends on extrinsic signals experienced during their developmental progression in vivo. This process can be overridden during inflammation by the opposing regulatory effects of type I and II IFN as well as the mTOR inhibition.
- 24 February 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (7) , 1642-1652
Open AccessIFNs Reset the Differential Capacity of Human Monocyte Subsets to Produce IL-12 in Response to Microbial Stimulation
Human primary monocytes are composed of a minor, more mature CD16+(CD14low/neg) population and a major CD16neg(CD14+) subset. The specific functions of CD16+ versus CD16neg monocytes in steady state or inflammation remain poorly understood. In previous work, we found that IL-12 is selectively produced by the CD16+ subset in response to the protozoan pathogen, Toxoplasma gondii. In this study, we demonstrated that this differential responsiveness correlates with the presence of an IFN-induced transcriptional signature in CD16+ monocytes already at baseline. Consistent with this observation, we found that in vitro IFN-γ priming overcomes the defect in the IL-12 response of the CD16neg subset. In contrast, pretreatment with IFN-γ had only a minor effect on IL-12p40 secretion by the CD16+ population. Moreover, inhibition of the mTOR pathway also selectively increased the IL-12 response in CD16neg but not in CD16+ monocytes. We further demonstrate that in contrast to IFN-γ, IFN-α fails to promote IL-12 production by the CD16neg subset and blocks the effect of IFN-γ priming. Based on these observations, we propose that the acquisition of IL-12 responsiveness by peripheral blood monocyte subsets depends on extrinsic signals experienced during their developmental progression in vivo. This process can be overridden during inflammation by the opposing regulatory effects of type I and II IFN as well as the mTOR inhibition.
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 93 (suppl 4) , e20211178
Vascular events induced by SARS-CoV-2 and their impact in oral health
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 93 (suppl 4) , e20211178
Open AccessVascular events induced by SARS-CoV-2 and their impact in oral health
- 1 March 2017
- Published by Elsevier in Human Pathology
- Vol. 61, 97-104
Epidermal growth factor receptor as an adverse survival predictor in squamous cell carcinoma of the penis
- 1 March 2017
- Published by Elsevier in Human Pathology
- Vol. 61, 97-104
Epidermal growth factor receptor as an adverse survival predictor in squamous cell carcinoma of the penis